Sort By
Publication Year
Deposit Date
Title
Type
Access
Publication Year
2019 (1)
2017 (1)
2016 (1)
2015 (4)
2014 (2)
2013 (1)
2012 (1)
2011 (4)
2010 (3)
2007 (1)
2005 (2)
2003 (1)
Version
M-Rank
M13 (1)
M21 (5)
M21a (2)
M22 (4)
M23 (7)

Soskić, Sanja S.

Link to this page

Authority KeyName Variants
orcid::0000-0002-9482-6940
  • Soskić, Sanja S. (18)
  • Mečanin, Sanja (4)
Projects

Author's Bibliography

Effects of IGF-1 on the cardiovascular system

Obradović, Milan M.; Zafirović, Sonja; Soskić, Sanja S.; Stanimirović, Julijana; Trpković, Andreja; Jevremović, Danimir P.; Isenović, Esma R.

(2019)

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Soskić, Sanja S.
AU  - Stanimirović, Julijana
AU  - Trpković, Andreja
AU  - Jevremović, Danimir P.
AU  - Isenović, Esma R.
PY  - 2019
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8483
AB  - Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.
T2  - Current Pharmaceutical Design
T1  - Effects of IGF-1 on the cardiovascular system
VL  - 25
IS  - 35
SP  - 3715
EP  - 3725
DO  - 10.2174/1381612825666191106091507
ER  - 
@article{
author = "Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Stanimirović, Julijana and Trpković, Andreja and Jevremović, Danimir P. and Isenović, Esma R.",
year = "2019",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/8483",
abstract = "Cardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.",
journal = "Current Pharmaceutical Design",
title = "Effects of IGF-1 on the cardiovascular system",
volume = "25",
number = "35",
pages = "3715-3725",
doi = "10.2174/1381612825666191106091507"
}
2
3
3

Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Smiljenic, Dragana; Kovacev-Zavisic, Branka; Srdić-Galić, Biljana; Soskić, Sanja S.; Isenović, Esma R.

(2017)

@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2017",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1589",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity (Authors Reply)",
volume = "68",
number = "6",
pages = "561-561",
doi = "10.1177/0003319717691435"
}
1

Asocijacija promena antropometrijskih i metaboličkih parametara i aktivnosti enzima antioksidativne zaštite sa polimorfizmom LEP G2548A u genu za leptin kod gojaznih osoba u Srbiji

Soskić, Sanja S.

(Универзитет у Београду, Биолошки факултет, 2016)

@phdthesis{
author = "Soskić, Sanja S.",
year = "2016",
url = "http://eteze.bg.ac.rs/application/showtheses?thesesId=4822, https://fedorabg.bg.ac.rs/fedora/get/o:15140/bdef:Content/download, http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=1025142194, http://nardus.mpn.gov.rs/123456789/7890, http://vinar.vin.bg.ac.rs/handle/123456789/7317",
abstract = "Stopa rasta gojaznosti predstavlja glavni javni zdravstveni problem. U Evropi je njena učestalost u opsegu 10-25% kod muškaraca i 10-30% kod žena. Prevalenca gojaznosti je povećana u Srbiji i ona je postala značajan zdravstveni problem kod odraslih u Srbiji: do 54% ispitanika odraslog stanovništva je gojazno. Gojaznost je bolest koja se definiše kao patološka akumulacija telesne masne mase, koja može nastati kao rezultat povećanog unosa energije i smanjene potrošnje energije. Danas se smatra da je genetska predispozicija za nastanak gojaznosti jedan od glavnih faktora rizika za pojedince, ali identifikaciju gena koji su uključeni u nastanak gojaznosti je još uvek teško razjasniti. S obzirom na činjenicu da je koncentracija leptina znatno povećana kod gojaznih osoba, a istovremeno je proporcionalna telesnoj masi, gen leptina (LEP) je procenjivan u odnosu na genetičke varijante koje bi eventualno mogle biti u vezi sa patofiziologijom gojaznosti i njenim komplikacijama. Leptin je hormon protein kodiran genom gojaznosti (ob), a sintetiše ga pretežno belo masno tkivo. Centralni nervni sistem, tačnije jedra hipotalamusa su meta u kojima leptin ispoljava većinu svojih efekata na metabolizam energije. Leptin ostvaruje nekoliko sistemskih efekata kao što: su smanjenje unosa hrane, povećanje energetske potrošnje, kao i smanjenje metaboličke efikasnosti. Pored toga, leptin utiče na širok spektar bioloških funkcija poput metabolizma lipida i glukoze, sintezu glukokortikoida kao i insulina, a postoji sve više dokaza da je leptin uključen i u patogenezu inflamatornih i autoimunih bolesti. Adekvatne masne naslage i koncentracija leptina smanjuju potrebu za unosom hrane, a omogućavaju potrošnju energije putem raznih neuroendokrinih osa i autonomne aktivnosti. Retki sindromi gojaznosti su povezani sa mutacijama LEP gena kod ljudi. Česta genetička varijanta jednog nukleotida u 5 'promotorskom regionu koji se sastoji u supstituciji G u A na nukleotidu (nt) -2548 (LEP G-2548A, -dbSNPID rs7799039) uzvodno od starta transkripcije ATG u promotoru LEP je povezan sa varijacijamakoncentracije leptina u plazmi i indeksom telesne mase (BMI) kod gojaznih osoba..., The growth in obesity rates presents a major public health concern. In Europe, its prevalence is within the range of 10–25% in men and 10–30% in women. The prevalence of obesity increased in Serbia and it became a significant public health problem among adults: up to 54% examinees of adult populations were obese. Obesity is a disease defined as abnormal accumulation of body fat mass, which may arise as a result of increased energy intake and decreased energy expenditure. Genetic predisposition to obesity has been reported as a major risk factor for individuals, but identification of the involved genes is still difficult to elucidate. Considering the fact that leptin concentration is significantly increased in obese persons and at the same time is proportional with body weight, the leptin gene (LEP) has been evaluated for polymorphisms that could potentially be related to the pathophysiology of obesity and its complications. Leptin is a protein hormone encoded by the obese (ob) gene, and is synthesized predominantly by white adipose cells. Central nervous system, namely hypothalamic nuclei, is the target where leptin exerts most of its effects on energy metabolism. Leptin has several systemic effects such as decreases food intake, increases energy expenditure, and decreases metabolic efficiency. In addition, leptin has been shown to influence a wide spectrum of biological functions, such as lipid and glucose metabolism, synthesis of glucocorticoids as well as insulin, and there is an increasing evidence that leptin is involved in the pathogenesis of inflammatory, and autoimmune diseases. Adequate fat stores and leptin concentrations decrease the need for food intake however, allow expenditure of energy via a variety of neuroendocrine axes, autonomic outputs and activities. Rare obesity syndromes are associated with mutations of LEP in humans. A common single nucleotide polymorphism within the 5′ promoter region consisting in G to A substitution at nucleotide (nt) -2548 (LEP G-2548A, -dbSNPID rs7799039) upstream of the ATG start site, in LEP promoter has been associated with variations in the concentrations of plasma leptin and body mass index (BMI) in obese individuals. It has been shown that LEP G-2548A polymorphism influences expressionand secretion of leptin in adipose tissue...",
publisher = "Универзитет у Београду, Биолошки факултет",
journal = "Универзитет у Београду",
title = "Asocijacija promena antropometrijskih i metaboličkih parametara i aktivnosti enzima antioksidativne zaštite sa polimorfizmom LEP G2548A u genu za leptin kod gojaznih osoba u Srbiji"
}

High-Sensitivity C-Reactive Protein and Statin Initiation

Trpković, Andreja; Stanimirović, Julijana; Rizzo, Manfredi; Resanović, Ivana; Soskić, Sanja S.; Jevremovic, Danimir; Isenović, Esma R.

(2015)

@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Rizzo, Manfredi and Resanović, Ivana and Soskić, Sanja S. and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/613",
abstract = "The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.",
journal = "Angiology",
title = "High-Sensitivity C-Reactive Protein and Statin Initiation",
volume = "66",
number = "6",
pages = "503-507",
doi = "10.1177/0003319714543000"
}
1
2

Interrelatedness between C-reactive protein and oxidized low-density lipoprotein

Obradović, Milan M.; Trpković, Andreja; Bajić, Vladan P.; Soskić, Sanja S.; Jovanović, Aleksandra; Stanimirović, Julijana; Panic, Milos; Isenović, Esma R.

(2015)

@article{
author = "Obradović, Milan M. and Trpković, Andreja and Bajić, Vladan P. and Soskić, Sanja S. and Jovanović, Aleksandra and Stanimirović, Julijana and Panic, Milos and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/281",
abstract = "C-reactive protein (CRP) is a marker of inflammation. Atherosclerosis is now recognized as inflammatory disease, and it seems that CRP directly contributes to atherogenesis. Oxidation of low-density lipoprotein (LDL) molecule increases the uptake of lipid products by macrophages leading to cholesterol accumulation and subsequent foam cell formation. The elevated levels of high sensitivity CRP (hsCRP) and oxidized LDL (OxLDL) in the blood were found to be associated with cardiovascular diseases (CVD). In this review, we highlighted the evidence that CRP and OxLDL are involved in interrelated (patho) physiological pathways. The findings on association between hsCRP and OxLDL in the clinical setting will be also summarized.",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Interrelatedness between C-reactive protein and oxidized low-density lipoprotein",
volume = "53",
number = "1",
pages = "29-34",
doi = "10.1515/cclm-2014-0590"
}
3
14
8
11

Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Zavisic, Branka Kovacev; Mitrovic, Milena; Smiljenic, Dragana; Soskić, Sanja S.; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Zavisic, Branka Kovacev
AU  - Mitrovic, Milena
AU  - Smiljenic, Dragana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/395
AB  - Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.
T2  - Angiology
T1  - Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile
VL  - 66
IS  - 3
SP  - 237
EP  - 243
DO  - 10.1177/0003319714528569
ER  - 
@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Zavisic, Branka Kovacev and Mitrovic, Milena and Smiljenic, Dragana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/395",
abstract = "Vitamin D deficiency is associated with cardiometabolic risk factors (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We studied 50 obese patients (body mass index [BMI]: 43.5 +/- 9.2 kg/m(2)) and 36 normal weight participants (BMI: 22.6 +/- 1.9 kg/m(2)). The prevalence of vitamin D deficiency (25-hydroxyvitamin D, 25(OH)D LT 50 nmol/L) was 88% among obese patients and 31% among nonobese individuals; 25(OH)D levels were lower in the obese group (27.3 +/- 13.7 vs 64.6 +/- 21.3 nmol/L; P LT .001). There was a negative correlation between vitamin D level and anthropometric indicators of obesity: BMI (r = -0.64; P LT .001), waist circumference (r = -0.59; P LT .001), and body fat percentage (r = -0.64; P LT .001) as well as with fasting plasma insulin (r = -0.35; P LT .001) and homeostasis model assessment of insulin resistance (r = -0.35; P LT .001). In conclusion, we observed a higher prevalence of vitamin D deficiency among obese participants and this was associated with a proatherogenic cardiometabolic risk profile.",
journal = "Angiology",
title = "Obesity and Vitamin D Deficiency: Trends to Promote a More Proatherogenic Cardiometabolic Risk Profile",
volume = "66",
number = "3",
pages = "237-243",
doi = "10.1177/0003319714528569"
}
27
30
29

Vitamin D and Dysfunctional Adipose Tissue in Obesity

Stokić, Edita; Kupusinac, Aleksandar; Tomic-Naglic, Dragana; Smiljenic, Dragana; Kovacev-Zavisic, Branka; Srdić-Galić, Biljana; Soskić, Sanja S.; Isenović, Esma R.

(2015)

TY  - JOUR
AU  - Stokić, Edita
AU  - Kupusinac, Aleksandar
AU  - Tomic-Naglic, Dragana
AU  - Smiljenic, Dragana
AU  - Kovacev-Zavisic, Branka
AU  - Srdić-Galić, Biljana
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/673
AB  - Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.
T2  - Angiology
T1  - Vitamin D and Dysfunctional Adipose Tissue in Obesity
VL  - 66
IS  - 7
SP  - 613
EP  - 618
DO  - 10.1177/0003319714543512
ER  - 
@article{
author = "Stokić, Edita and Kupusinac, Aleksandar and Tomic-Naglic, Dragana and Smiljenic, Dragana and Kovacev-Zavisic, Branka and Srdić-Galić, Biljana and Soskić, Sanja S. and Isenović, Esma R.",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/673",
abstract = "Vitamin D deficiency and dysfunctional adipose tissue are involved in the development of cardiometabolic disturbances (eg, hypertension, insulin resistance, type 2 diabetes mellitus, obesity, and dyslipidemia). We evaluated the relation between vitamin D and adipocytokines derived from adipose tissue. We studied 50 obese individuals who were classified into different subgroups according to medians of observed anthropometric parameters (body mass index, body fat percentage, waist circumference, and trunk fat mass). There was a negative correlation between vitamin D level and leptin and resistin (r = -.61, P LT .01), while a positive association with adiponectin concentrations was found (r = .7, P LT .001). Trend estimation showed that increase in vitamin D level is accompanied by intensive increase in adiponectin concentrations (growth coefficient: 12.13). In conclusion, a positive trend was established between vitamin D and the protective adipocytokine adiponectin. The clinical relevance of this relationship needs to be investigated in larger studies.",
journal = "Angiology",
title = "Vitamin D and Dysfunctional Adipose Tissue in Obesity",
volume = "66",
number = "7",
pages = "613-618",
doi = "10.1177/0003319714543512"
}
2
23
23
25

The relationship between vitamin D and obesity

Soskić, Sanja S.; Stokić, Edita; Isenović, Esma R.

(2014)

@article{
author = "Soskić, Sanja S. and Stokić, Edita and Isenović, Esma R.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6013",
abstract = "Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other diseases. Concentrations of 25-hydroxyvitamin D (25(OH) D) (25D) are considered as the best indicator of total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may establish a role for Vitamin D supplementation in individuals at increased CV risk.",
journal = "Current Medical Research and Opinion",
title = "The relationship between vitamin D and obesity",
volume = "30",
number = "6",
pages = "1197-1199",
doi = "10.1185/03007995.2014.900004"
}
1
22
16
24

Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study

Soskić, Sanja S.; Stokić, Edita; Obradović, Milan M.; Sudar, Emina; Tanić, Nasta; Kupusinac, Aleksandar; Đorđević, Jelena D.; Isenović, Esma R.

(2014)

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Stokić, Edita
AU  - Obradović, Milan M.
AU  - Sudar, Emina
AU  - Tanić, Nasta
AU  - Kupusinac, Aleksandar
AU  - Đorđević, Jelena D.
AU  - Isenović, Esma R.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/239
AB  - Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.
T2  - Clinical Lipidology
T1  - Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study
VL  - 9
IS  - 5
SP  - 505
EP  - 513
DO  - 10.2217/CLP.14.42
ER  - 
@article{
author = "Soskić, Sanja S. and Stokić, Edita and Obradović, Milan M. and Sudar, Emina and Tanić, Nasta and Kupusinac, Aleksandar and Đorđević, Jelena D. and Isenović, Esma R.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/239",
abstract = "Aim: The aim of this pilot study was to investigate possible associations of LEP promoter polymorphism LEP G-2548A and obesity-associated metabolic and antropometric parameters in obese population. Materials and methods: Group of 31 patients with hyperalimentary type of obesity (mean age: 39.26 +/- 11.45 years; BMI: 41.51 +/- 9.22 kg/m(2)) and 36 healthy, nonobese, normal weight subjects (mean age: 33.55 +/- 6.46 years; BMI: 22.63 +/- 1.94 kg/m(2)) were studied. Blood samples were collected for DNA isolation, serum leptin and serum lipids measurements. LEP G-2548A genotypes were determined by PCR restriction fragment length polymorphism based analyses. Results: No significant differences in genotype and allele frequencies of the LEP G-2548A polymorphism were detected between obese and normal weight subjects. No association was found between this polymorphism and BMI. Obese subjects had statistically significant increase in serum leptin levels compared with control, while no association between leptin concentration and LEP polymorphism LEP G-2548A was found. There is a statistically significant association of LEP G-2548A genotypes with LDL (p LT 0.05), LDL/HDL ratio (p LT 0.001), apoB (p LT 0.01), body weight (p LT 0.001) and waist circumference (p LT 0.001). Conclusion: Our findings indicate that there is an association between LEP G-2548A polymorphism and metabolic and anthropometric parameters in obese patients in a Serbian population.",
journal = "Clinical Lipidology",
title = "Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study",
volume = "9",
number = "5",
pages = "505-513",
doi = "10.2217/CLP.14.42"
}
1
2

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

Rizzo, Manfredi; Rizvi, Ali A.; Sudar, Emina; Soskić, Sanja S.; Obradović, Milan M.; Montalto, Giuseppe; Boutjdir, Mohamed; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2013)

@article{
author = "Rizzo, Manfredi and Rizvi, Ali A. and Sudar, Emina and Soskić, Sanja S. and Obradović, Milan M. and Montalto, Giuseppe and Boutjdir, Mohamed and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5565",
abstract = "Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is assumed that blood glucose levels represent a significant regulator. Recent evidence indicates that ghrelin can increase myocardial contractility, enhance vasodilatation, and has protective effect from myocardial damage. It has been shown that ghrelin may improve cardiac function through growth hormone (GH)-dependent mechanisms but there is also evidence to suggest that ghrelins cardioprotective activity is independent of GH. Recent data demonstrate that ghrelin can influence key events in atherogenesis. Thus, ghrelin may be a new target for the treatment of some cardiovascular diseases. In this review, we consider the current literature focusing on ghrelin as a potential antiatherogenic agent in the treatment of various pathophysiological conditions.",
journal = "Current Pharmaceutical Design",
title = "A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin",
volume = "19",
number = "27",
pages = "4953-4963",
doi = "10.2174/1381612811319270018"
}
17
19
19

Ghrelin, obesity and atherosclerosis

Sudar, Emina; Soskić, Sanja S.; Zarić, Božidarka; Rašić-Milutinović, Zorica; Smiljanić, Katarina; Radak, Đorđe J.; Mikhailidis, Dimitri P.; Rizzo, Manfredi; Isenović, Esma R.

(2012)

TY  - CHAP
AU  - Sudar, Emina
AU  - Soskić, Sanja S.
AU  - Zarić, Božidarka
AU  - Rašić-Milutinović, Zorica
AU  - Smiljanić, Katarina
AU  - Radak, Đorđe J.
AU  - Mikhailidis, Dimitri P.
AU  - Rizzo, Manfredi
AU  - Isenović, Esma R.
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/8685
AB  - Cardiovascular disease (CVD) is common cause of death in humans and its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality. This inflammatory process, triggered by the presence of lipids in the vascular wall, and encompasses a complex interaction among inflammatory cells, vascular elements, and lipoproteins through the expression of several adhesion molecules and cytokines. Obesity is a risk factor for CVD but this association is not fully understood. Altered levels of obesity related peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence indicates that ghrelin features several cardiovascular activities, including increased myocardial contractility, vasodilatation and protection from myocardial infarction. Recent data demonstrate that ghrelin can influence important key events in atherogenesis and thus they may play a role in atherosclerosis. In this review we present the latest data from recent animal and clinical studies which focus on a novel approach to ghrelin as a potential therapeutic agent in the treatment of a complex disease like atherosclerosis. Thus, ghrelin may become a new therapeutic target for the treatment of CVD. Further studies are necessary to investigate the potential mechanisms involved in the effects of ghrelin on the cardiovascular system.
T2  - Ghrelin: Production, Action Mechanisms and Physiological Effects
T1  - Ghrelin, obesity and atherosclerosis
SP  - 111
EP  - 126
ER  - 
@article{
author = "Sudar, Emina and Soskić, Sanja S. and Zarić, Božidarka and Rašić-Milutinović, Zorica and Smiljanić, Katarina and Radak, Đorđe J. and Mikhailidis, Dimitri P. and Rizzo, Manfredi and Isenović, Esma R.",
year = "2012",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/8685",
abstract = "Cardiovascular disease (CVD) is common cause of death in humans and its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality. This inflammatory process, triggered by the presence of lipids in the vascular wall, and encompasses a complex interaction among inflammatory cells, vascular elements, and lipoproteins through the expression of several adhesion molecules and cytokines. Obesity is a risk factor for CVD but this association is not fully understood. Altered levels of obesity related peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence indicates that ghrelin features several cardiovascular activities, including increased myocardial contractility, vasodilatation and protection from myocardial infarction. Recent data demonstrate that ghrelin can influence important key events in atherogenesis and thus they may play a role in atherosclerosis. In this review we present the latest data from recent animal and clinical studies which focus on a novel approach to ghrelin as a potential therapeutic agent in the treatment of a complex disease like atherosclerosis. Thus, ghrelin may become a new therapeutic target for the treatment of CVD. Further studies are necessary to investigate the potential mechanisms involved in the effects of ghrelin on the cardiovascular system.",
journal = "Ghrelin: Production, Action Mechanisms and Physiological Effects",
title = "Ghrelin, obesity and atherosclerosis",
pages = "111-126"
}

Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats

Sudar, Emina; Dobutovic, Branislava; Soskić, Sanja S.; Mandušić, Vesna; Žakula, Zorica; Misirkić, Maja; Vucicevic, Ljubica; Janjetović, Kristina D.; Trajković, Vladimir S.; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2011)

TY  - JOUR
AU  - Sudar, Emina
AU  - Dobutovic, Branislava
AU  - Soskić, Sanja S.
AU  - Mandušić, Vesna
AU  - Žakula, Zorica
AU  - Misirkić, Maja
AU  - Vucicevic, Ljubica
AU  - Janjetović, Kristina D.
AU  - Trajković, Vladimir S.
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4317
AB  - The purpose of this study was to examine the effects of ghrelin on protein kinase B (Akt) and mitogen-activated protein kinase p42/44 (ERK1/2) activation as well as ghrelin effects on inducible nitric oxide (NO) synthase (iNOS; for gene Nos2) activity/expression in rat hearts. Male Wistar rats were treated with ghrelin (0.3 nmol/5 mu l) or an equal volume of phosphate-buffered saline, injected every 24 h into the lateral cerebral ventricle for 5 days and 2 h after the last treatment the animals were sacrificed. Serum NO, l-arginine (l-Arg), and arginase activity were measured spectrophotometrically. For phosphorylation of Akt, ERK1/2, and iNOS protein expression, Western blot method was used. The expression of Nos2 mRNA was measured by the quantitative real-time polymerase chain reaction (qRT-PCR). Treatment with ghrelin significantly increased NO production in serum by 1.4-fold compared with control. The concentration of l-Arg was significantly higher in ghrelin-treated rats than in control while arginase activity was significantly lower in ghrelin-treated than in control hearts. Ghrelin treatment increased phosphorylation of Akt by 1.9-fold and ERK1/2 by 1.6-fold and increased iNOS expression by 2.5-fold compared with control. In addition, ghrelin treatment increased Nos2 gene expression by 2.2-fold as determined by qRT-PCR. These results indicate that ghrelin regulation of iNOS expression/activity is mediated via Akt/ERK1/2 signaling pathway. These results may be relevant to understanding molecular mechanisms underlying direct cardiovascular actions of ghrelin.
T2  - Journal of Physiology and Biochemistry
T1  - Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats
VL  - 67
IS  - 2
SP  - 195
EP  - 204
DO  - 10.1007/s13105-010-0063-1
ER  - 
@article{
author = "Sudar, Emina and Dobutovic, Branislava and Soskić, Sanja S. and Mandušić, Vesna and Žakula, Zorica and Misirkić, Maja and Vucicevic, Ljubica and Janjetović, Kristina D. and Trajković, Vladimir S. and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4317",
abstract = "The purpose of this study was to examine the effects of ghrelin on protein kinase B (Akt) and mitogen-activated protein kinase p42/44 (ERK1/2) activation as well as ghrelin effects on inducible nitric oxide (NO) synthase (iNOS; for gene Nos2) activity/expression in rat hearts. Male Wistar rats were treated with ghrelin (0.3 nmol/5 mu l) or an equal volume of phosphate-buffered saline, injected every 24 h into the lateral cerebral ventricle for 5 days and 2 h after the last treatment the animals were sacrificed. Serum NO, l-arginine (l-Arg), and arginase activity were measured spectrophotometrically. For phosphorylation of Akt, ERK1/2, and iNOS protein expression, Western blot method was used. The expression of Nos2 mRNA was measured by the quantitative real-time polymerase chain reaction (qRT-PCR). Treatment with ghrelin significantly increased NO production in serum by 1.4-fold compared with control. The concentration of l-Arg was significantly higher in ghrelin-treated rats than in control while arginase activity was significantly lower in ghrelin-treated than in control hearts. Ghrelin treatment increased phosphorylation of Akt by 1.9-fold and ERK1/2 by 1.6-fold and increased iNOS expression by 2.5-fold compared with control. In addition, ghrelin treatment increased Nos2 gene expression by 2.2-fold as determined by qRT-PCR. These results indicate that ghrelin regulation of iNOS expression/activity is mediated via Akt/ERK1/2 signaling pathway. These results may be relevant to understanding molecular mechanisms underlying direct cardiovascular actions of ghrelin.",
journal = "Journal of Physiology and Biochemistry",
title = "Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats",
volume = "67",
number = "2",
pages = "195-204",
doi = "10.1007/s13105-010-0063-1"
}
21
19
23

Peroxisome Proliferator-Activated Receptors and Atherosclerosis

Soskić, Sanja S.; Dobutovic, Branislava D.; Sudar, Emina; Obradović, Milan M.; Nikolić, Dragana; Zarić, Božidarka; Stojanovic, Srdan D.; Stokić, Edita; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2011)

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Dobutovic, Branislava D.
AU  - Sudar, Emina
AU  - Obradović, Milan M.
AU  - Nikolić, Dragana
AU  - Zarić, Božidarka
AU  - Stojanovic, Srdan D.
AU  - Stokić, Edita
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4519
AB  - The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.
T2  - Angiology
T1  - Peroxisome Proliferator-Activated Receptors and Atherosclerosis
VL  - 62
IS  - 7
SP  - 523
EP  - 534
DO  - 10.1177/0003319711401012
ER  - 
@article{
author = "Soskić, Sanja S. and Dobutovic, Branislava D. and Sudar, Emina and Obradović, Milan M. and Nikolić, Dragana and Zarić, Božidarka and Stojanovic, Srdan D. and Stokić, Edita and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4519",
abstract = "The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPAR alpha, -gamma, and -delta/beta, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, which might present new approaches involved in the antiatherosclerotic effects revealed in this review. In addition, in this review we are presenting latest data from recent performed clinical studies which have focus on novel approach to PPARs agonists as potential therapeutic agents in the treatment of complex disease such as atherosclerosis.",
journal = "Angiology",
title = "Peroxisome Proliferator-Activated Receptors and Atherosclerosis",
volume = "62",
number = "7",
pages = "523-534",
doi = "10.1177/0003319711401012"
}
17
22
25

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

Haidara, Mohamed A.; Mikhailidis, Dimitri P.; Yassin, Hanaa Z.; Dobutovic, Branislava; Smiljanić, Katarina; Soskić, Sanja S.; Mousa, Shaker A.; Rizzo, Manfredi; Isenović, Esma R.

(2011)

@article{
author = "Haidara, Mohamed A. and Mikhailidis, Dimitri P. and Yassin, Hanaa Z. and Dobutovic, Branislava and Smiljanić, Katarina and Soskić, Sanja S. and Mousa, Shaker A. and Rizzo, Manfredi and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4662",
abstract = "The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other hand, it is difficult to counteract the development of CV complications by using conventional antioxidants. Indeed, interest has focused on strategies that enhance the removal of ROS using either antioxidants or drugs that enhance endogenous antioxidant defense. Although these strategies have been effective in laboratory experiments, several clinical trials have shown that they do not reduce CV events, and in some cases antioxidants have actually worsened the outcome. More research is needed in this field.",
journal = "Current Pharmaceutical Design",
title = "Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome",
volume = "17",
number = "33",
pages = "3699-3712",
doi = "10.2174/138161211798220882"
}
11
14
15

Effect of Insulin on Adiponectin and Adiponectin Receptor-1 Expression in Rats with Streptozotocin-induced Type 2 Diabetes

Al-Hashem, Fahaid; Ibrahim, Ibrahim; Bastawy, Nermeen; Rateb, Moshira; Haidara, Mohamed A.; Dallak, Mohammed; Soskić, Sanja S.; Bin-Jaliah, Ismaeel; Isenović, Esma R.

(2011)

TY  - JOUR
AU  - Al-Hashem, Fahaid
AU  - Ibrahim, Ibrahim
AU  - Bastawy, Nermeen
AU  - Rateb, Moshira
AU  - Haidara, Mohamed A.
AU  - Dallak, Mohammed
AU  - Soskić, Sanja S.
AU  - Bin-Jaliah, Ismaeel
AU  - Isenović, Esma R.
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4472
AB  - The present study was designed to investigate the effect of insulin on insulin resistance (IR), plasma adiponectin level and expression of adiponectin receptors 1 (AdipoR1) in obese and streptozotocin-induced type 2 diabetic rats. Male Sprague-Dowley rats were randomized to control group and 3 obese experimental groups. Type 2 diabetic mellitus was induced in the 3(rd) and 4(th) experimental groups by given 30 mg/kg of a single dose streptozotocin via intraperitoneal injection (i.p.). Fourth group was treated with i.p. 1 IU insulin/kg/day for 6 days before end of the experiment which lasts for 8 weeks while same amount of normal saline was i.p. given to other group. At the end of the study (8 weeks), plasma levels of adiponectin, triglycerides (TO), cholesterol, fasting blood glucose and insulin were measured. Obesity index (01) and IR were calculated. AdipoR1 mRNA levels in the soleus muscle tissue were semi-quantitated. Hyperlipidemia, hyperinsulinemia and hyperglycemia were observed ill both obese and diabetic rats, which were accompanied by hypoadiponectinemia and down regulation of AdipoR1 expression as compared to the control rats. Adiponectin was negatively correlated with all the biochemical parameters assessed. Insulin treatment significantly improved these metabolic abnormalities and effectively restored adiponectin and AdipoR1 to the control level. In conclusion, adiponectin and its receptor-associated cascade may be aberrantly regulated in both obesity and type 2 diabetes and targeting adiponectin and its receptors may offer a novel therapy against obesity and type 2 diabetes.
T2  - Journal of Health Science
T1  - Effect of Insulin on Adiponectin and Adiponectin Receptor-1 Expression in Rats with Streptozotocin-induced Type 2 Diabetes
VL  - 57
IS  - 4
SP  - 334
EP  - 340
DO  - 10.1248/jhs.57.334
ER  - 
@article{
author = "Al-Hashem, Fahaid and Ibrahim, Ibrahim and Bastawy, Nermeen and Rateb, Moshira and Haidara, Mohamed A. and Dallak, Mohammed and Soskić, Sanja S. and Bin-Jaliah, Ismaeel and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4472",
abstract = "The present study was designed to investigate the effect of insulin on insulin resistance (IR), plasma adiponectin level and expression of adiponectin receptors 1 (AdipoR1) in obese and streptozotocin-induced type 2 diabetic rats. Male Sprague-Dowley rats were randomized to control group and 3 obese experimental groups. Type 2 diabetic mellitus was induced in the 3(rd) and 4(th) experimental groups by given 30 mg/kg of a single dose streptozotocin via intraperitoneal injection (i.p.). Fourth group was treated with i.p. 1 IU insulin/kg/day for 6 days before end of the experiment which lasts for 8 weeks while same amount of normal saline was i.p. given to other group. At the end of the study (8 weeks), plasma levels of adiponectin, triglycerides (TO), cholesterol, fasting blood glucose and insulin were measured. Obesity index (01) and IR were calculated. AdipoR1 mRNA levels in the soleus muscle tissue were semi-quantitated. Hyperlipidemia, hyperinsulinemia and hyperglycemia were observed ill both obese and diabetic rats, which were accompanied by hypoadiponectinemia and down regulation of AdipoR1 expression as compared to the control rats. Adiponectin was negatively correlated with all the biochemical parameters assessed. Insulin treatment significantly improved these metabolic abnormalities and effectively restored adiponectin and AdipoR1 to the control level. In conclusion, adiponectin and its receptor-associated cascade may be aberrantly regulated in both obesity and type 2 diabetes and targeting adiponectin and its receptors may offer a novel therapy against obesity and type 2 diabetes.",
journal = "Journal of Health Science",
title = "Effect of Insulin on Adiponectin and Adiponectin Receptor-1 Expression in Rats with Streptozotocin-induced Type 2 Diabetes",
volume = "57",
number = "4",
pages = "334-340",
doi = "10.1248/jhs.57.334"
}
2
1

Levels of sCD40 Ligand in Chronic and Acute Coronary Syndromes and its Relation to Angiographic Extent of Coronary Arterial Narrowing

Fouad, Hanan H.; Al-Dera, Husain; Bakhoum, Sameh W.; Rashed, Laila A.; Sayed, Rehab H.; Rateb, Moshira A.; Haidara, Mohamed A.; Soskić, Sanja S.; Isenović, Esma R.

(2010)

TY  - JOUR
AU  - Fouad, Hanan H.
AU  - Al-Dera, Husain
AU  - Bakhoum, Sameh W.
AU  - Rashed, Laila A.
AU  - Sayed, Rehab H.
AU  - Rateb, Moshira A.
AU  - Haidara, Mohamed A.
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2010
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4039
AB  - We determined the serum levels of soluble CD40 ligand (sCD4OL) in patients with chronic coronary artery disease (CAD) and acute coronary syndrome (ACS). Patients with unstable angina (UA) and myocardial infarction (MI) showed significantly higher levels (P LT .001) of sCD4OL compared with patients with stable angina (SA) and controls; particularly, high levels occurred in patients with UA (UA: 9.23 +/- 2.92, MI: 7.38 +/- 1.05, SA: 4.42 +/- 1.08; control: 4.01 +/- 0.87 ng/mL). There was no significant difference in sCD4OL levels between patients with UA and MI or between patients with SA and controls. Levels of sCD4OL did not show any significant correlation with peak creatine kinase (CK), CK-MB isoenzyme activity in patients with MI, troponin T serum levels in patients with UA or with culprit vessel (CV) complexity score (CVCS), type of CV lesion, or vessel score in patients with UA or MI. These results suggest that CD40L plays a pathogenic role in triggering ACS.
T2  - Angiology
T1  - Levels of sCD40 Ligand in Chronic and Acute Coronary Syndromes and its Relation to Angiographic Extent of Coronary Arterial Narrowing
VL  - 61
IS  - 6
SP  - 567
EP  - 573
DO  - 10.1177/0003319709356785
ER  - 
@article{
author = "Fouad, Hanan H. and Al-Dera, Husain and Bakhoum, Sameh W. and Rashed, Laila A. and Sayed, Rehab H. and Rateb, Moshira A. and Haidara, Mohamed A. and Soskić, Sanja S. and Isenović, Esma R.",
year = "2010",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4039",
abstract = "We determined the serum levels of soluble CD40 ligand (sCD4OL) in patients with chronic coronary artery disease (CAD) and acute coronary syndrome (ACS). Patients with unstable angina (UA) and myocardial infarction (MI) showed significantly higher levels (P LT .001) of sCD4OL compared with patients with stable angina (SA) and controls; particularly, high levels occurred in patients with UA (UA: 9.23 +/- 2.92, MI: 7.38 +/- 1.05, SA: 4.42 +/- 1.08; control: 4.01 +/- 0.87 ng/mL). There was no significant difference in sCD4OL levels between patients with UA and MI or between patients with SA and controls. Levels of sCD4OL did not show any significant correlation with peak creatine kinase (CK), CK-MB isoenzyme activity in patients with MI, troponin T serum levels in patients with UA or with culprit vessel (CV) complexity score (CVCS), type of CV lesion, or vessel score in patients with UA or MI. These results suggest that CD40L plays a pathogenic role in triggering ACS.",
journal = "Angiology",
title = "Levels of sCD40 Ligand in Chronic and Acute Coronary Syndromes and its Relation to Angiographic Extent of Coronary Arterial Narrowing",
volume = "61",
number = "6",
pages = "567-573",
doi = "10.1177/0003319709356785"
}
6
8
8

Pro12ala Gene Polymorphism in the Peroxisome Proliferator-Activated Receptor Gamma as a Risk Factor for the Onset of Type 2 Diabetes Mellitus in the Serbian Population

Soskić, Sanja S.; Stanković, Aleksandra; Đurić, Tamara; Živković, Maja; Ristic, P.; Anđelković, Z.; Sumarac-Dumanovic, Mirjana; Alavantić, Dragan

(2010)

TY  - JOUR
AU  - Soskić, Sanja S.
AU  - Stanković, Aleksandra
AU  - Đurić, Tamara
AU  - Živković, Maja
AU  - Ristic, P.
AU  - Anđelković, Z.
AU  - Sumarac-Dumanovic, Mirjana
AU  - Alavantić, Dragan
PY  - 2010
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4047
AB  - The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a gene candidate for the onset of type 2 diabetes mellitus (T2DM). We investigated the association of the PPAR gamma Pro12Ala gene with the onset of T2DM for the first time in the Serbian population. The study population consisted of 197 controls and 163 T2DM patients. The 12Ala allele tended to be more frequent in the group of T2DM patients (0.11) compared to the control subjects (0.09). The results from this study indicate that the PPAR gamma(2) 12Ala allele presents a non-significant risk factor for T2DM development in the Serbian population.
T2  - Archives of biological sciences
T1  - Pro12ala Gene Polymorphism in the Peroxisome Proliferator-Activated Receptor Gamma as a Risk Factor for the Onset of Type 2 Diabetes Mellitus in the Serbian Population
VL  - 62
IS  - 2
SP  - 263
EP  - 270
DO  - 10.2298/ABS1002263S
ER  - 
@article{
author = "Soskić, Sanja S. and Stanković, Aleksandra and Đurić, Tamara and Živković, Maja and Ristic, P. and Anđelković, Z. and Sumarac-Dumanovic, Mirjana and Alavantić, Dragan",
year = "2010",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4047",
abstract = "The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a gene candidate for the onset of type 2 diabetes mellitus (T2DM). We investigated the association of the PPAR gamma Pro12Ala gene with the onset of T2DM for the first time in the Serbian population. The study population consisted of 197 controls and 163 T2DM patients. The 12Ala allele tended to be more frequent in the group of T2DM patients (0.11) compared to the control subjects (0.09). The results from this study indicate that the PPAR gamma(2) 12Ala allele presents a non-significant risk factor for T2DM development in the Serbian population.",
journal = "Archives of biological sciences",
title = "Pro12ala Gene Polymorphism in the Peroxisome Proliferator-Activated Receptor Gamma as a Risk Factor for the Onset of Type 2 Diabetes Mellitus in the Serbian Population",
volume = "62",
number = "2",
pages = "263-270",
doi = "10.2298/ABS1002263S"
}
1
2
2

Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation

Isenović, Esma R.; Soskić, Sanja S.; Trpković, Andreja; Dobutovic, Branislava; Popović, Milan; Gluvić, Zoran; Putnikovic, Biljana; Marche, Pierre

(2010)

@article{
author = "Isenović, Esma R. and Soskić, Sanja S. and Trpković, Andreja and Dobutovic, Branislava and Popović, Milan and Gluvić, Zoran and Putnikovic, Biljana and Marche, Pierre",
year = "2010",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4209",
abstract = "Vascular smooth muscle cells (VSMC) respond to arterial wall injury by intimal proliferation and play a key role in atherogenesis by proliferating and migrating excessively in response to repeated injury, such as hypertension and atherosclerosis. In contrast, fully differentiated, quiescent VSMC allow arterial vasodilatation and vasoconstriction. Exaggerated and uncontrolled VSMC proliferation appears therefore to be a common feature of both atherosclerosis and hypertension. Signal transduction pathways in eukaryotic cells integrate diverse extracellular signals, and regulate complex biological responses such as growth, differentiation and death. One group of proline-directed Ser/Thr protein kinases, the mitogen-activated protein kinases (MAPKs), plays a central role in these signalling pathways. Much attention has focused in recent years on subfamilies of MAPKs, the extracellular signal regulated kinases (ERKs). Here we overview the work on ERKs 1 to 2, emphasising when possible their biological activities in VSMC proliferation. It is clear from numerosus studies including our own, that ERK1/ERK2 pathway has an imoprtant role in VSMC proliferation induced by insulin (INS) and thrombin. Despite the physiological and pathophysiological importance of INS and thrombin, possible signal transduction pathways involved in INS and thrombin regulation of VSMCs proliferation remains poorly understood. Thus, this review examines recent findings in signalling mechanisms involved in INS and thrombin-triggered VSMCs proliferation with particular emphasis on ERK1/2 signalling pathways. Future investigations should now focus on the mechanisms of MAPK activation which might therefore represent a new mechanism involved in the antiproliferative effect revealed in this review.",
journal = "Current Pharmaceutical Design",
title = "Insulin, Thrombin, ERK1/2 Kinase and Vascular Smooth Muscle Cells Proliferation",
volume = "16",
number = "35",
pages = "3895-3902",
doi = "10.2174/138161210794454987"
}
18
19
21

ACE I/D and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian males

Đurić, Tamara; Stanković, Aleksandra; Živković, Maja; Mečanin, Sanja; Alavantić, Dragan

(2007)

TY  - CONF
AU  - Đurić, Tamara
AU  - Stanković, Aleksandra
AU  - Živković, Maja
AU  - Mečanin, Sanja
AU  - Alavantić, Dragan
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6668
C3  - Atherosclerosis Supplements
T1  - ACE I/D and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian males
VL  - 8
IS  - 1
SP  - 50
EP  - 50
DO  - 10.1016/S1567-5688(07)71141-8
ER  - 
@conference{
author = "Đurić, Tamara and Stanković, Aleksandra and Živković, Maja and Mečanin, Sanja and Alavantić, Dragan",
year = "2007",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6668",
journal = "Atherosclerosis Supplements",
title = "ACE I/D and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian males",
volume = "8",
number = "1",
pages = "50-50",
doi = "10.1016/S1567-5688(07)71141-8"
}

Association of MMP-3 5A/6A and NOS3 G894T polymorphisms with hypertension and serum hdl cholesterol level

Đurić, Tamara; Živković, Maja; Mečanin, Sanja; Caranovic, O; Stanković, Aleksandra; Alavantić, Dragan

(2005)

TY  - CONF
AU  - Đurić, Tamara
AU  - Živković, Maja
AU  - Mečanin, Sanja
AU  - Caranovic, O
AU  - Stanković, Aleksandra
AU  - Alavantić, Dragan
PY  - 2005
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6504
C3  - Atherosclerosis Supplements
T1  - Association of MMP-3 5A/6A and NOS3 G894T polymorphisms with hypertension and serum hdl cholesterol level
VL  - 6
IS  - 1
SP  - 17
EP  - 18
DO  - 10.1016/S1567-5688(05)80067-4
ER  - 
@conference{
author = "Đurić, Tamara and Živković, Maja and Mečanin, Sanja and Caranovic, O and Stanković, Aleksandra and Alavantić, Dragan",
year = "2005",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6504",
journal = "Atherosclerosis Supplements",
title = "Association of MMP-3 5A/6A and NOS3 G894T polymorphisms with hypertension and serum hdl cholesterol level",
volume = "6",
number = "1",
pages = "17-18",
doi = "10.1016/S1567-5688(05)80067-4"
}

Endothelial NOS G894T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population

Đurić, Tamara; Živković, Maja; Stanković, Aleksandra; Mečanin, Sanja; Alavantić, Dragan

(2005)

TY  - JOUR
AU  - Đurić, Tamara
AU  - Živković, Maja
AU  - Stanković, Aleksandra
AU  - Mečanin, Sanja
AU  - Alavantić, Dragan
PY  - 2005
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2949
AB  - The incidence of hypertension is increasing and it is more common in man than in women. Up to date, MMP-3 5A/6A polymorphism has been associated with artery stiffening and elevated blood pressure, whereas results considering association of endothelial NOS (eNOS) G894T polymorphism with hypertension are controversial. The aim of our study was to analyze the possible association of eNOS G894T and MMP-3 5A/6A gene polymorphisms with hypertension in Serbian population. Study sample consisted of 172 hypertensive and 200 normotensive subjects divided by gender. Both female and male group was truncated according to age. All subjects were genotyped for MMP-3 5A/6A and eNOS G894T polymorphism. There was a significantly higher (P LT 0.05) prevalence of 5A/5A genotype in hypertensive females compared to normotensive ones (19.30% vs. 10.84%) even more pronounced in group GT = 50 years, according to its recessive effect. In young males ( LT 40 years), we found 3.7-fold increased risk for hypertension associated with allele 6A (P LT 0.01), and 8.1-fold with genotype 6A/6A (P=0.01) according to recessive model. We found no association of eNOS G894T polymorphism with hypertension. These results indicate that there were gender-and age-specific differences in association of MMP-3 5A/6A polymorphism with hyperin Serbian population.
T2  - Journal of Clinical Laboratory Analysis
T1  - Endothelial NOS G894T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population
VL  - 19
IS  - 6
SP  - 241
EP  - 246
DO  - 10.1002/jcla.20085
ER  - 
@article{
author = "Đurić, Tamara and Živković, Maja and Stanković, Aleksandra and Mečanin, Sanja and Alavantić, Dragan",
year = "2005",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/2949",
abstract = "The incidence of hypertension is increasing and it is more common in man than in women. Up to date, MMP-3 5A/6A polymorphism has been associated with artery stiffening and elevated blood pressure, whereas results considering association of endothelial NOS (eNOS) G894T polymorphism with hypertension are controversial. The aim of our study was to analyze the possible association of eNOS G894T and MMP-3 5A/6A gene polymorphisms with hypertension in Serbian population. Study sample consisted of 172 hypertensive and 200 normotensive subjects divided by gender. Both female and male group was truncated according to age. All subjects were genotyped for MMP-3 5A/6A and eNOS G894T polymorphism. There was a significantly higher (P LT 0.05) prevalence of 5A/5A genotype in hypertensive females compared to normotensive ones (19.30% vs. 10.84%) even more pronounced in group GT = 50 years, according to its recessive effect. In young males ( LT 40 years), we found 3.7-fold increased risk for hypertension associated with allele 6A (P LT 0.01), and 8.1-fold with genotype 6A/6A (P=0.01) according to recessive model. We found no association of eNOS G894T polymorphism with hypertension. These results indicate that there were gender-and age-specific differences in association of MMP-3 5A/6A polymorphism with hyperin Serbian population.",
journal = "Journal of Clinical Laboratory Analysis",
title = "Endothelial NOS G894T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population",
volume = "19",
number = "6",
pages = "241-246",
doi = "10.1002/jcla.20085"
}
10
10
12

Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on serum lipid levels in Serbian population

Glišić, Sanja; Stanković, Srboljub J.; Đurić, Tamara; Mečanin, Sanja; Majkic-Singh, N

(2003)

TY  - CONF
AU  - Glišić, Sanja
AU  - Stanković, Srboljub J.
AU  - Đurić, Tamara
AU  - Mečanin, Sanja
AU  - Majkic-Singh, N
PY  - 2003
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6373
AB  - Lipoprotein lipase (LPL) gene mutations might be one of genetic factors for the development of hyperlipoproteinemia in apoE2/2 homozygotes and E2 heterozygotes. Fasting serum lipids and analyses of the LPL gene Asn291Ser polymorphism and apolipoprotein (apo) E common polymorphism were performed in 201 healthy subjects. An interaction between the LPL/apoE DNA polymorphisms on serum total cholesterol (TC) and triglycerides (TG) variation was found. Individuals carrying the E2+/Ser291 allele had significantly higher mean TC (P LT 0.01) and TG (P LT 0.05) and lower high density lipoprotein cholesterol (HDLC) (P LT 0.05) compared with E2+/ Asn291. The results of this study demonstrate relationship between LPL and apoE DNA polymorphism. and serum lipid levels.
T1  - Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on serum lipid levels in Serbian population
SP  - 413
EP  - 416
ER  - 
@conference{
author = "Glišić, Sanja and Stanković, Srboljub J. and Đurić, Tamara and Mečanin, Sanja and Majkic-Singh, N",
year = "2003",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6373",
abstract = "Lipoprotein lipase (LPL) gene mutations might be one of genetic factors for the development of hyperlipoproteinemia in apoE2/2 homozygotes and E2 heterozygotes. Fasting serum lipids and analyses of the LPL gene Asn291Ser polymorphism and apolipoprotein (apo) E common polymorphism were performed in 201 healthy subjects. An interaction between the LPL/apoE DNA polymorphisms on serum total cholesterol (TC) and triglycerides (TG) variation was found. Individuals carrying the E2+/Ser291 allele had significantly higher mean TC (P LT 0.01) and TG (P LT 0.05) and lower high density lipoprotein cholesterol (HDLC) (P LT 0.05) compared with E2+/ Asn291. The results of this study demonstrate relationship between LPL and apoE DNA polymorphism. and serum lipid levels.",
title = "Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on serum lipid levels in Serbian population",
pages = "413-416"
}